Research Articles - Macular Degeneration
No other retinal condition affects more people in developed countries than the dry form of age-related macular degeneration (AMD). Of the estimated 30 million people in the world with AMD, approximately 90 percent have dry — the other 10 percent have the wet form.
When it comes to restoring vision to the blind, researchers may soon bypass the eye entirely and go straight to the brain.
Using nanoparticles to provide sustained delivery of the drug retinylamine, researchers at Case Western Reserve University slowed disease progression in a mouse model of macular degeneration. The emerging treatment worked by preventing the accumulation of vision-robbing, toxic waste products in the retina, which is the hallmark of age-related macular degeneration (AMD) and Stargardt disease, the most common form of juvenile macular degeneration.
- Nutritional supplements are big business. In 2013, the industry generated $32 billion in revenue, and that number is expected to double by 2021. There are dozens of supplement alternatives available for many health conditions, and it can often be difficult for a consumer to determine what supplement will work best, if at all, given the great deal of misinformation and erroneous claims.
- November 17, 2014 - The Foundation Fighting Blindness (FFB) recently updated its website by adding Spanish language translations of some of its resource materials to better serve patients and others interested in learning about retinal diseases.Those wishing to view the materials in Spanish may click on the link En Espanol in the resources section of the Foundation’s website.
- Jan. 15, 2015 – Six months after the launch of a clinical trial for a bone marrow stem-cell treatment targeting retinal disorders, researchers are reporting encouraging preliminary findings.The first six patients enrolled in the on-going clinical trial, taking place at the University of California Davis Eye Center, tolerated the procedure well without any serious adverse events. Vision in most of the treated eyes also improved modestly after treatment.
In the latest chapter of an ongoing saga involving Avastin, a cancer drug used off-label to treat wet age-related macular degeneration (AMD), the U.S. Department of Veterans Affairs recently halted use of the drug in its hospitals. A statement issued by the VA in late September advised its physicians to “consider alternate therapies” until an investigation of Avastin is complete. The VA will then reassess the use of Avastin and offer guidance.